Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells

Publisher： Karger

E-ISSN： 1423-0232|75|3-4|159-168

ISSN： 0030-2414

Source： Oncology, Vol.75, Iss.3-4, 2008-10, pp. : 159-168

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cells: Regulation of Expression of Cancer-Related Genes by Estradiol and Tamoxifen

By  

Current Signal Transduction Therapy, Vol. 3, Iss. 1, 2008-01 ,pp. : 7-21

Bentham Science Publishers

Access to resources Recommend Favorite

Immunohistochemical Detection of Breast Cancer Stem Cells in Hormone Receptor-Positive Breast Cancer and Their Role in Response to Endocrine Therapy and Clinical Outcome

By  

Oncology, Vol. 82, Iss. 3, 2012-03 ,pp. : 168-174

Karger

Access to resources Recommend Favorite

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor‐positive breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 3, 2015-08 ,pp. : 686-697

John Wiley & Sons Inc

Access to resources Recommend Favorite

Active smoking and the risk of estrogen receptor‐positive and triple‐negative breast cancer among women ages 20 to 44 years

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 1-6

Karger

Access to resources Recommend Favorite